News | Stereotactic Body Radiation Therapy (SBRT) | April 06, 2018

First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System

New clinical trial evaluates use of online-adaptive stereotactic body radiation therapy approach in the treatment of oligometastases

First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System

April 6, 2018 — Accuray Inc. and Erasmus MC announced the first patient has been successfully treated using an online-adaptive (OA) approach together with the CyberKnife System. The patient, treated for oligometastases in the pelvic region, is part of a new clinical trial conducted at Erasmus MC, the largest university medical center in the Netherlands, evaluating OA stereotactic body radiation therapy (SBRT) delivered by the CyberKnife platform. The trial brings the hospital one step closer to its goal of providing individual, personalized medicine.

"At Erasmus MC our goal is to use innovative approaches to provide customized, effective treatments that help extend or improve the quality of life of people diagnosed with cancer, regardless of the stage of their cancer diagnosis," said J.J. Nuyttens, M.D., Ph.D., radiation oncologist, Department of Radiation Oncology, Erasmus MC. "We initiated this trial because we want to improve local cancer control and minimize toxicities in people with pelvic or intra-abdominal oligometastases."

Oligometastastic disease occurs when cancer cells from the primary tumor travel to other parts of the body and form a small number (less than six) of lesions. The cancerous cells are in an intermediate state; they are no longer confined to their initial location nor have they spread widely throughout the body. Radiation treatment of oligometastatic disease in the pelvic or intra-abdominal area is challenging because of the close proximity of healthy organs very sensitive to radiation. From one day to the next there can be a significant variation in the position of these organs, and it can be difficult to account for the changes in their location on a daily basis.

To address this issue, Accuray and Erasmus MC are partnering to develop an integrated, advanced imaging solution tailored for use with the CyberKnife System. The purpose is to enable clinicians to adapt the treatment plan to daily anatomical changes within the patient. According to Nuyttens, "this OA-SBRT strategy provided the treated patient with an optimal combination of dose to the tumor and sparing of the surrounding healthy organs."

This study is a non-randomized single arm phase II clinical trial evaluating the use of OA-SBRT for the treatment of oligometastatic disease in the pelvic or para-aortic region. In total, 53 patients will be enrolled and will be followed for three years. A prescription dose of 45 Gy will be delivered in five fractions by the CyberKnife System. The primary study objectives are to evaluate local control, survival and toxicity.

For more information: www.accuray.com

 

Related Content

Elekta Expands Mosaiq Oncology Information System With PalabraApps
News | Oncology Information Management Systems (OIMS) | April 20, 2018
April 20, 2018 — Elekta announced that it is making a strategic investment in PalabraApps LLC to advance the developm
This image, taken with Canon's Aquilion One, shows a lung with metastases from bowel cancer.

This image, taken with Canon’s Aquilion One, shows a lung with metastases from bowel cancer. Image courtesy of Canon.

Feature | Lung Cancer | April 18, 2018 | Jeff Zagoudis
In recent years, low-dose computed tomography (CT) screening has emerged as a proven, effective method to detect lung
Chest X-ray AI Algorithm Correctly Identifies Lung Disease for Dubai Health Authority
Feature | Artificial Intelligence | April 17, 2018
The Dubai Health Authority (DHA) announced the preliminary results of a chest X-ray artificial intelligence (AI)...
Varian Launches Velocity 4.0 Cancer Imaging Software
Technology | Treatment Planning | April 16, 2018
April 16, 2018 — Varian announced a new version of its Velocity cancer imaging software that includes Rapidsphere, a
First Patient Treated on Mevion's S250i Proton Therapy System
News | Proton Therapy | April 05, 2018
Mevion Medical Systems announced the treatment of the first patient in the world on the Mevion S250i Proton Therapy...
ASTRO Updates Guidelines for Palliative Lung Radiation Therapy
News | Radiation Therapy | April 05, 2018
The American Society for Radiation Oncology (ASTRO) issued an update to its clinical guideline for the use of...
News | Endoscopes | April 02, 2018
Results from a recent prospective trial found the Wide Area Transepithelial Sampling with 3D Tissue Analysis (WATS3D)...
Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study
News | Computed Tomography (CT) | March 27, 2018
March 27, 2018 — Edwards Lifesciences Corp.
Combination Radiotherapy Beneficial in Treating Prostate Cancer
News | Prostate Cancer | March 27, 2018
March 27, 2018 — While there are many treatment options for men with...
Loyola Study Finds Medical Students Receive Little Formal Instruction in Radiation Oncology
News | Radiation Therapy | March 26, 2018
Medical school students receive little formal instruction in radiation oncology, a Loyola study has found.
Overlay Init